Bonesupport Holding AB (publ)

OM:BONEX 주식 리포트

시가총액: SEK 14.5b

Bonesupport Holding 과거 순이익 실적

과거 기준 점검 4/6

Bonesupport Holding은 연평균 53.5%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 수입이 30% 증가했습니다. 매출은 연평균 38.5%의 비율로 증가했습니다. Bonesupport Holding의 자기자본이익률은 19.7%이고 순이익률은 15.2%입니다.

핵심 정보

53.46%

순이익 성장률

53.50%

주당순이익(EPS) 성장률

Biotechs 산업 성장률0.71%
매출 성장률38.49%
자기자본이익률19.72%
순이익률15.23%
다음 순이익 업데이트16 Jul 2026

최근 과거 실적 업데이트

Bonesupport Holding's (STO:BONEX) Soft Earnings Are Actually Better Than They Appear

Jul 23
Bonesupport Holding's (STO:BONEX) Soft Earnings Are Actually Better Than They Appear

Recent updates

Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models

Apr 25
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models

BONEX: Clinical Pilot Infection Outcomes Will Support Future Upside Potential

Analysts have raised their price target for Bonesupport Holding by about SEK 10.60 to SEK 377.17, citing updated assumptions that include a slightly higher discount rate, adjusted revenue growth expectations, a revised profit margin outlook, and a lower future P/E multiple. What's in the News Bonesupport Holding announced the first publication of a US clinical pilot study on the surgical technique and outcomes of CERAMENT G in trauma.

BONEX: Clinical Pilot Outcomes And 2026 Sales Outlook Will Support Future Upside Potential

Analysts have revised their price target on Bonesupport Holding to SEK 366.6. The update reflects an unchanged fair value along with adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Publication of a US clinical pilot study in OTA International highlighting surgical technique and outcomes for CERAMENT G in trauma cases, providing practical, real world guidance for clinicians considering the product in fracture related infections and osteomyelitis (Key Developments).

BONEX: Clinical Pilot Outcomes And 2025 Guidance Will Support Future Upside Potential

Analysts have kept their SEK price target for Bonesupport Holding unchanged at SEK 366.60, citing broadly consistent assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these factors support a steady valuation view.

Slow Trauma Center Adoption And Regulatory Hurdles Will Eventually Support A Healthier Business Mix

Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products used to treat complex bone infections and defects. What are the underlying business or industry changes driving this perspective?

BONEX: Clinical Pilot Results And Strong Guidance Will Support Long-Term Upside Potential

Analysts have trimmed their price target on Bonesupport Holding by SEK 4 to SEK 366.6. This reflects updated assumptions around discount rates, revenue growth and profitability, while keeping future P/E expectations broadly in line with previous views. What's in the News Bonesupport announced the first publication of a US clinical pilot study on the surgical technique and outcomes of CERAMENT G in trauma, giving clinicians practical, real world insights into its use in trauma cases.

US Trauma Expansion And New Surgical Uses Will Transform This Bone Regeneration Specialist

Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products such as CERAMENT G and CERAMENT V, for use in complex bone infections and orthopedic procedures. What are the underlying business or industry changes driving this perspective?

BONEX: De Novo Shift Will Support Long Term Upside Potential

Analysts have slightly trimmed their fair value estimate for Bonesupport Holding to SEK370.6, from SEK374.6, reflecting minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions, while keeping the overall thesis broadly intact. What's in the News Bonesupport issued earnings guidance for Q4 2025, with net sales expected at 313 MSEK at constant exchange rates, based on company guidance for that period (company guidance).

Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?

Feb 12
Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?

BONEX: De Novo Pathway Shift Will Support Long Term Upside Potential

Analysts have kept their fair value estimate for Bonesupport Holding steady at SEK374.60 per share. The latest price target update mainly reflects small technical tweaks to the discount rate and future P/E assumptions rather than a shift in the core outlook.

BONEX: De Novo Review Shift Will Support Long Term Upside Potential

Analysts have trimmed their price target for Bonesupport Holding to SEK 374.60 from SEK 391.20, citing slightly lower assumptions for revenue growth and profit margins, along with a higher future P/E multiple. What's in the News Bonesupport Holding issued earnings guidance for the fourth quarter of 2025 with net sales expected at SEK 313 M, based on constant exchange rates (Corporate guidance).

BONEX: De Novo Pathway Shift Will Support Long Term Upside Potential

Analysts have kept their fair value estimate for Bonesupport Holding steady at SEK391.20, with only minor tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This suggests their overall view on the company’s long term potential is essentially unchanged.

BONEX: De Novo Pathway Shift Will Support Strong Future Market Position

Analysts have modestly raised their price target on Bonesupport Holding, citing a slightly lower discount rate and improved visibility into sustaining approximately 38 percent revenue growth and robust 31 percent profit margins. Together, these factors support a fair value of SEK 391.20 per share.

BONEX: Hip Infection Study Success Will Drive Stronger Future Clinical And Market Position

Analysts have modestly raised their price target on Bonesupport Holding to SEK 391.2 per share from SEK 391.2 per share, reflecting largely unchanged long term assumptions on the discount rate, revenue growth, profit margins and future valuation multiples. What's in the News Positive top line data from the CeraHip clinical study show that CERAMENT G enabled successful single stage revision surgery for periprosthetic joint infection of the hip, with no re infections reported over 24 months of follow up (Key Developments).

BONEX: Positive Study Results Will Support Improvements In Hip Infection Outcomes

Analysts have adjusted their price target for Bonesupport Holding, maintaining it at SEK 391.20. Recent evaluations indicate steady expectations in light of updated discount rates and continued confidence in the company's growth and profitability outlook.

Bonesupport Holding AB (publ) (STO:BONEX) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

Nov 22
Bonesupport Holding AB (publ) (STO:BONEX) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

BONEX: Clinical Study Results Will Drive Long-Term Patient Outcome Improvements

Bonesupport Holding's analyst price target has been updated downward from SEK 401.80 to SEK 391.20, as analysts factor in slightly softer revenue growth forecasts and a higher discount rate. What's in the News Bonesupport announced positive results from a clinical study showing significantly improved patient-reported outcomes for CERAMENT G in single-stage revision surgery for periprosthetic joint infection of the hip (Key Developments).

Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models

Oct 28
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models

Positive Clinical Results And US Launch Will Drive Future Success

Analysts have revised their price target for Bonesupport Holding from SEK 419.75 to SEK 401.80. This change reflects adjustments to growth and profitability assumptions.

Bonesupport Holding AB (publ)'s (STO:BONEX) Shares May Have Run Too Fast Too Soon

Aug 25
Bonesupport Holding AB (publ)'s (STO:BONEX) Shares May Have Run Too Fast Too Soon

Bonesupport Holding's (STO:BONEX) Soft Earnings Are Actually Better Than They Appear

Jul 23
Bonesupport Holding's (STO:BONEX) Soft Earnings Are Actually Better Than They Appear

Bonesupport Holding AB (publ)'s (STO:BONEX) Intrinsic Value Is Potentially 80% Above Its Share Price

Jun 28
Bonesupport Holding AB (publ)'s (STO:BONEX) Intrinsic Value Is Potentially 80% Above Its Share Price

Analyst Estimates: Here's What Brokers Think Of Bonesupport Holding AB (publ) (STO:BONEX) After Its First-Quarter Report

Apr 28
Analyst Estimates: Here's What Brokers Think Of Bonesupport Holding AB (publ) (STO:BONEX) After Its First-Quarter Report
User avatar

CERAMENT G's US Launch And CERAMENT V's FDA Submission Will Expand Global Presence

CERAMENT G's rapid U.S. penetration addresses a significant market need, likely causing notable revenue growth due to its strong clinical backing.

kr445 - That's What Analysts Think Bonesupport Holding AB (publ) (STO:BONEX) Is Worth After These Results

Mar 01
kr445 - That's What Analysts Think Bonesupport Holding AB (publ) (STO:BONEX) Is Worth After These Results

Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders

Oct 31
Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders

매출 및 비용 세부 내역

Bonesupport Holding가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

OM:BONEX 매출, 비용 및 순이익 (SEK Millions)
날짜매출순이익일반관리비연구개발비
31 Mar 261,21518574193
31 Dec 251,17514271991
30 Sep 251,11915270590
30 Jun 251,06214867789
31 Mar 2599812265786
31 Dec 2489913460976
30 Sep 248149157572
30 Jun 2473528953965
31 Mar 2465626749859
31 Dec 2359124546257
30 Sep 2352221442054
30 Jun 23448-3038354
31 Mar 23382-5134253
31 Dec 22329-6831253
30 Sep 22287-7227953
30 Jun 22257-7124951
31 Mar 22234-8223653
31 Dec 21213-8622153
30 Sep 21205-8821255
30 Jun 21198-9621455
31 Mar 21182-9219754
31 Dec 20181-10120158
30 Sep 20174-11520760
30 Jun 20165-12720466
31 Mar 20166-15122768
31 Dec 19155-16122669
30 Sep 19132-16621368
30 Jun 19108-19121567
31 Mar 1998-18219968
31 Dec 1897-17619266
30 Sep 18101-18218168
30 Jun 18119-14616365
31 Mar 18128-13214866
31 Dec 17129-12915061
30 Sep 17132-11215356
30 Jun 17126-12415454
31 Mar 17114-12416042
31 Dec 16105-11014038
31 Dec 1562-608819

양질의 수익: BONEX는 고품질 수익을 보유하고 있습니다.

이익 마진 증가: BONEX의 현재 순 이익률 (15.2%)은 지난해 (12.3%)보다 높습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: BONEX는 지난 5년 동안 흑자전환하며 연평균 53.5%의 수익 성장을 기록했습니다.

성장 가속화: 지난 1년간 BONEX 의 수익 증가율(51.3%)은 5년 평균(연간 53.5%)보다 낮습니다.

수익 대 산업: BONEX의 지난 1년 수익 증가율(51.3%)은 Biotechs 업계의 45%를 상회했습니다.

자기자본이익률

높은 ROE: BONEX의 자본 수익률(19.7%)은 낮음으로 평가됩니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/04/30 06:26
종가2026/04/30 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Bonesupport Holding AB (publ)는 8명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
null nullABG Sundal Collier
Erik CasselDanske Bank
Kristofer Liljeberg-SvenssonDNB Carnegie